




Abstract—Pharmacokinetics are used to model drug 
concentrations in the body.  These predictions can be combined 
with pharmacodynamic response surface models that predict the 
effect of multiple drugs acting on the body.  This study combined 
several pharmacokinetic and pharmacodynamic models to predict 
“adequate anesthesia.”  These predictions were compared to 
observations in patients.  While these specific model combinations 
are not accurate predictors of anesthesia for the recovery of 
responsiveness and tracheal intubation, a few combinations are 
reasonable predictors of the loss of responsiveness and also for the 
analgesia necessary for the first skin incision.  The Schnider 
propofol model and a fentanyl scaling factor of 1.2 are empirically 
the most accurate PK models in combination with the 
pharmacodynamic models used. 
 
I. INTRODUCTION 
esponse surfaces have been used to describe the 
pharmacological effect of two drugs at once.  The x and y-
axes are typically the independent variables in drug 
concentration units.  The z-axis is typically the predicted effect 
of the drugs in combination.  In the realm of anesthesia, the 
anesthetic concentrations can be estimated by pharmacokinetic 
(PK) models.  Pharmacodynamic (PD) models predict the 
level of anesthetic effect as a function of drug concentration.  
This observational study evaluates how accurately a 
combination of pharmacokinetic and pharmacodynamic 
models predicted the level of anesthesia in 24 patients 
undergoing abdominal laproscopic surgery.    
 
II. METHODS 
A. Study Design 
This observational study was designed to assess the 
accuracy of combined pharmacokinetic and pharmacodynamic 
(PK-PD) models in the operating room to predict adequate 
anesthesia for four clinical milestones: 1) loss of 
responsiveness, 2) laryngoscopy and tracheal intubation, 3) the 
first skin incision, and 4) the recovery of responsiveness at the 
end of surgery.  This study was only observational, and had 
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minimal impact on the “standard practice” of the 
anesthesiologist.  Two types of data were collected 
intraoperatively: 1) drug dosing information and 2) 
observations of the patient responses and nonresponses at 
clinical milestones.  Comparison of the PK-PD combined 
model predictions with the patient observations was performed 
post hoc. 
B. Subjects and Observations at Clinical Milestones 
With institutional review board approval from the 
University Hospital and informed consent of the patients, we 
studied 24, ASA physical status I, II, and III, patients (11 
males and 13 females) scheduled for abdominal laparoscopic 
surgery under total intravenous anesthesia.  All patients denied 
having cardiovascular, hepatic, or renal disease or a history of 
alcohol or drug abuse.  The anesthetic regimen was limited to 
propofol for sedation, and remifentanil and fentanyl for 
analgesia.   
Propofol and remifentanil syringes were loaded into 
separate infusion pumps (Medfusion 3010a, Medex, Inc., 
Dublin, OH, USA).  After the patient entered the OR, the 
primed remifentanil and propofol infusion lines were attached 
at the patient’s wrist.  This decreased the delay of drug 
delivery by minimizing the tubing deadspace flushed by the IV 
drip.  The anesthetists administered drug boluses for both 
induction and maintenance through the second IV access port 
distal from the patient.  An intra-lab software interface 
collected data from the two infusion pumps.  A research nurse 
and a graduate student observer recorded drug boluses given 
manually. 
C. Pharmacokinetic Modeling 
The modeling and assessment of the accuracy of the 
combined PK-PD model predictions occurred post hoc.  The 
PK simulations were run using the patient and drug dosing 
information.  Each drug (propofol, remifentanil, and fentanyl) 
had its own PK model.  The pharmacokinetics of each drug 
was assumed independent of the concentration of the other 
drugs.  We selected the Minto-Schnider model for remifentanil 
[1] and an adapted Shafer et al. model for fentanyl [2].  (The 
keo for the fentanyl model was calculated using the Tpeak [3] 
from Scott and Stanski’s data [4], instead of simply using the 
keo from their data.)  However, selecting the propofol model 
was not as straight forward. 
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We wished to use the Tackley model for propofol [5], since 
it had been used in the target-controlled-infusion system used 
for building the PD models of Kern et al. [6].  However, the 
Tackley model lacks an effect-site compartment while both the 
Gepts [7] and the Schnider [8] models include effect-site 
compartments.  The Gepts model lacks the PD data necessary 
to calculate the keo based on the time to peak effect.  
Therefore, we adapted the Tackley model to include an effect-
site compartment by using the k1e and ke0 variables of the 
Gepts and Schnider models.  Ultimately, four sets of rate 
constants were used for the propofol model—the Gepts model 
(G), the Schnider model (S), and the Tackley model using the 
Gepts effect-site (TG), and the Tackley model using the 
Schinder effect-site (TS).   
D. Pharmacodynamic Modeling 
The PD models used the modeled effect-site concentrations 
(Ceff) at the milestones of 1) LOR, 2) TI, 3) SI, and 4) ROR to 
predict the level of anesthesia.  The PD models predict the 
percentage of the population at those given drug 
concentrations that would be “adequately anesthetized” for 
each given surrogate measure.  Because the PK and PD 
models are independent of one another, they could be “mixed 
and matched,” producing different overall predictions for the 
depth of anesthesia.  The PK-PD combined model predictions 
were then compared to the actual patient responses and their 
accuracies were assessed.   
The response surfaces explicitly describe the PD interaction 
between propofol and remifentanil only.  To account for the 
analgesic effect of fentanyl (commonly used in standard 
practice), we used its relative opioid effect.  In other words, 
the Ceff of fentanyl was scaled by its relative potency to the 
Ceff of remifentanil.  However, the exact relative potency is 
difficult to ascertain from the literature.  Therefore, we chose 
to consider three different scaling factors: 1 ng/ml of fentanyl 
exerted a PD effect equal to the effect of 1.2, 1.7, or 2.4 ng/ml 
of remifentanil [9].  To calculate the total opioid 
concentration, normalized to remifentanil, the predicted 
concentrations of fentanyl were multiplied by their scaling 
factors and were added to the predicted concentration of 
remifentanil.  We estimated the PD effect (the likelihood of 
adequate anesthesia) from the total opioid Ceff and the 
propofol Ceff; the total opioid Ceff and propofol Ceff marked 
a data point on the response surface.   
Kern et al. used four surrogate measures to predict 
anesthetic effects of sedation and analgesia [6]; they used 1) 
the Observer’s Assessment of Alertness/Sedation (OAA/S) to 
predict the depth of hypnosis [10], both 2) responses to 
electrical tetany and 3) responses to shin algometry to predict 
the analgesia necessary for skin incision, and 4) responses to 
laryngoscopy to predict the analgesia necessary for 
laryngoscopy and endotracheal intubation.  Although the 
OAA/S follows a discrete scale from 1 to 5, Kern et al. treated 
OAA/S scores above and below 4 as binary states of sedation.  
Using the raw data of Kern et al., we recreated his sedation 
model using different criteria.  We calculated additional 
response surfaces for sedation with the criteria of OAA/S 
scores below 3 and 2 using the least-squares method.  Kern et 
al. assumed the steady-state plasma concentrations equaled the 
anesthetic Ceffs.  Thus, the Ceff estimates from the PK models 
were used as inputs into the PD models of Kern et al..   
Merten et al. observed actual surgical measures for 
responses to pain [11].  Response surfaces were created for the 
measures of 1) Laryngoscopy, 2) Endotracheal Intubation, and 
3) Awakening.  Laryngoscopy was repeated at three different 
concentration pairs.  Both laryngoscopy and endotracheal 
intubation were performed at pseudo-steady-state 
concentrations to approximate Ceffs.  Similarly, the Recovery 
of Consciousness was at the end of surgery when the anesthetic 
was eliminated by the body but was not marked by rapid 
changes in blood concentrations.  Ceff estimates from the PK 
models were used as inputs for the PD models of Merten et al..   
E. Data Analysis 
PK simulations used the dosing information gathered in the 
OR.  From the OR patient observations, we gathered the time 
points of the surgical stimuli.  We used the estimated Ceff 
pairs of propofol and total opioid (normalized to remifentanil) 
at these time points to calculate PD predictions appropriate for 
the surgical measure.  Each combined PK-PD model was 
treated as an entirely different scenario, so that the accuracy of 
each unique combination of PK-PD models could be evaluated 
for its accuracy relative to the population and the surgical 
measure.  Each prediction was also paired with an actual 
observed patient state of “responsive” or “nonresponsive.”   
For a given population PD model, a 50% or 95% prediction 
of adequate anesthesia defines the anesthetic concentrations 
needed to attain 100% anesthetic effect in 50% or 95% of the 
population for that stimulus.  These PD models come from 
pooled individual data.  However, when the population model 
is used to infer information about the individual, the meaning 
of the prediction changes somewhat.  For a PD prediction for 
an individual, we see what percentage of the population is 
expected to be anesthetized, and infer the likelihood of 
anesthesia for an individual.  Thus, for sedation PD models, a 
50% value describes the concentrations at which 50% of the 
population is 100% sedated and is taken as the likelihood of an 
“average” individual being completely sedated.  For PD 
models of noxious stimuli, the PD model predicted level of 
anesthesia refers to the percentage of the population that would 
be anesthetized and estimates the likelihood of the patient to 
not exhibit a heart rate or other somatic response at those 
anesthetic concentrations.   
The analyses are grouped by the clinical measure for which 
the adequacy of anesthesia was being predicted.  For each 
measure, the different PK and models were combined.  All the 
possible PK-PD model combinations are summarized in Table 
1 by the surgical measure of interest.   
The LOR and ROR PK-PD combined model predictions 
could not be tested simply at the LOR and ROR observation 
times as the recorded data did not include any “false positives” 




LOR and ROR observations were used.  These elapsed times 
were calculated from the first drug administered in the 
operating room until the observed LOR and from the last 
trocar removal and the beginning of wound closure until the 
observed ROR.  In contrast, the TI and SI data were easily 
analyzed directly from the recorded observations.   
For all surgical measures, we compared the PK-PD 
predictions to the observations of adequate anesthesia as a 
population using two different nonparametric tests (the two-
tailed Fisher exact test and the PK  test) and by the coefficient 
of determination (r2).  The two-tailed Fisher exact test was 
used to evaluate whether the associations between the 
observations and the PK-PD combined model predictions 
relative to the 50% and 95% levels of effect or isobols were 
statistically significant [12].  The PK is a measure of the 
accuracy with which the combined PK-PD models predict the 
observed patient states [13], [14].  r2 is a common “goodness-
of-fit” measure [12]. 
The two-tailed Fisher exact test analyzes 2x2 contingency 
tables for small sample sizes by computing the exact 
probability of that specific arrangement of data from all 
possible arrangements, with the hypothesis that the rows and 
columns are independent [12].  The number of 
“nonanesthetized” and “anesthetized” patients below and 
above a given isobol were tabulated.  To test the sedation LOR 
and ROR predictions, the two-tailed Fisher exact tests were 
used at the mean times relative to the 50% and 95% isobols.  
For TI and SI the Fisher exact tests were used on the PK-PD 
combined model predictions at the observed stimuli, relative to 
the 50% and 95% isobols.  The p-value for the two-tailed 
Fisher exact test was calculated using GraphPad InStat (v. 
3.05, 32 bit for Win 95/NT, GraphPad Software, San Diego, 
California, USA, www.graphpad.com).  A p-value < 0.005 or 
0.05 was considered extremely statistically significant or 
statistically significant, respectively, and represents the 
probability of the predictions and the observations as tabulated 
in the contingency table occurring by chance.   
We also used the prediction probability PK test (a 
nonparametric rank-order test) to assess the overall accuracy 
of the model predictions [13], [14].  This test is set up by 
pairing the PK-PD combined model predictions with the 
patient state.  In total, the PK statistic was used on four sets of 
data: 1) the LOR predictions at the mean time point, 2) the 
ROR predictions at the mean time, 3) the TI data, and 4) the SI 
data.  The PK was calculated using a macro written for Excel 
by and available from Warren D. Smith (copyright 1996).  
When PK = 1, the order of the model predictions always 
correctly predict the order of the patient state, whereas when 
PK = 0.5, the models do not predict the patient state.   
The coefficient of determination or r2 (the square of the 
Pearson product-moment correlation coefficient) is a measure 
of how much of the variability in the data is predicted by the 
PK-PD combined models [12].  Again, the mean and median 
data for the sedation predictions were not lumped.  The 
correlation coefficient was calculated in Excel.  An r2 = 1 




A. Recruitment and Data Collection 
All 24 patients enrolled, completed the study.  Data are 
presented as the mean ± standard deviation.  The mean age 
was 38.9 ± 12.4 years and the mean weight was 86.4 ± 22.6 
kg, and the mean height was 171.58 ± 8.99 cm.  Of the 24 
observed surgical cases, 15 were laproscopic 
cholecystectomies, 6 surgeries were laproscopic hernia repairs, 
and 3 were laproscopic nissen fundoplications.  The anesthetic 
was delivered by 2 experienced CRNAs in 16 cases, 2 third 
year residents in 2 cases, 2 second year residents in 3 cases, 
and a first year resident in 3 cases.   
Although propofol was the only intraoperative sedative, 
with two exceptions, the patients received midazolam (average 
dose of 1.61 mg, ± 0.49) prior to entering the operating room 
(OR).   (One of the patients declined midazolam and another 
TABLE 1 
PK-PD MODEL COMBINATIONS TESTED 
PK MODEL VARIATIONS 
SURGICAL MEASURE 
PROPOFOL PK MODELS FENTANYL: REMIFENTANIL RELATIVE POTENCY 
PD MODELS 
# OF POSSIBLE 
PK-PD MODEL 
COMBINATIONS 
Loss of Responsiveness 
Kern OAA/S 4-3 
Kern OAA/S 3-2 
Kern OAA/S 2-1 
Mertens Awakening 






4*3*3 = 36 
First Skin Incision Kern Algometry Kern Tetany 4*3*2 = 24 
Recovery of 
Responsiveness 
Tackley – Gepts 







Kern OAA/S 4-3 
Kern OAA/S 3-2 
Kern OAA/S 2-1 
Mertens Awakening 






patient received midazolam after arriving in the OR.)  
Remifentanil and fentanyl were the primary analgesics.  
Ketorolac tromethamine was also given in 13 cases late in the 
procedure for maintenance and post-operative pain 
management.  However, neither the kinetics nor the dynamics 
of ketorolac tromethamine were modeled.  The observations of 
patients at clinical milestones are summarized in Table 2.  
LOR was indicated during induction when the patient no 
longer responded to the anesthesiologist.  A heart rate 
response was indicated if there was a 20% increase in the 
patient heart rate within 1 minute after laryngoscopy and 
tracheal intubation or the first skin incision.  ROR was 
indicated when the patient obeyed simple commands by the 
anesthesiologist (such as “Open your eyes,” or “Please take a 
deep breath so we can take out your breathing tube.”)   
B. Combined PK-PD Model Predictions 
The likelihood of adequate anesthesia was calculated using 
the predicted propofol and total opioid (normalized to 
remifentanil) Ceff pairs and the appropriate PD models.  For a 
single patient at each clinical milestone, there were many 
different PK-PD combined model predictions, summarized in 
Table 2.  The best performing PK-PD combined model 
estimates are described below under Statistical Analysis.  The 
results of all 156 PK-PD model combinations for all clinical 
measures are available from the author upon request. 
C. Statistical Analysis 
For LOR and using the two-tailed Fisher exact test, all 48 of 
the PK-PD combinations resulted in statistically significant 
associations between the observations and model predictions 
relative to both 50% and 95% isobols at the mean LOR time.  
These results, with the specific models, are shown in Table 3, 
along with the top three performing model combinations at the 
mean and median times according to the PK and r
2 values.   
The statistical analysis showed PK-PD combined models 
predicting ROR to be less reliable than those predicting LOR.  
For the three lowest p-values from the two-tailed Fisher exact 
tests of the patient observations and PK-PD combined model 
predictions for ROR relative to the 50% and 95% isobols at 
the mean time, only three of 31 PK-PD combinations were 
statistically significant.  The associations for the other 28 PK-
PD combinations were not statistically significant.  The 
averaged p-values and the specific PK-PD combinations are 
summarized in Table 4 along with best PK and r
2 values and 
relevant models.   
TABLE 3 
SUMMARY OF THE STATISTICAL TESTS FOR THE COMBINED PK-PD MODELS 
PREDICTING LOR 
TEST 
































(top 3 scores) 




(top 3 scores) 
TG:1.2:3,2,M 0.6701 (0.1629) 
TG, TS, G, and S refer to the Tackley-Gepts, Tackley-Schnider, Gepts, 
and Schnider propofol PK sets, respectively. 
1.2, 1.7, and 2.4 are the three fentanyl relative potencies modeled.   
4, 3, 2, and M refer to the sedation PD models of Kern et al. for OAA/S < 
4, OAA/S < 3, OAA/S < 2, and the Merten’s Awakening.   
*’s refer to all applicable PK or PD models tested.   
 
TABLE 4 
SUMMARY OF THE STATISTICAL TESTS FOR THE COMBINED PK-PD MODELS 
PREDICTING ROR 
TEST 
AVERAGE OF TOP 












































TG, TS, G, and S refer to the Tackley-Gepts, Tackley-Schnider, Gepts, 
and Schnider propofol PK sets, respectively. 
1.2, 1.7, and 2.4 are the three fentanyl relative potencies modeled.   
4, 3, 2, and M refer to the sedation PD models of Kern et al. for OAA/S < 
4, OAA/S < 3, OAA/S < 2, and the Merten’s Awakening, respectively.   
TABLE 2 
OBSERVATIONS AND PHARMACOKINETIC CEFF ESTIMATES AT SURGICAL 
MILESTONES. 
SURGICAL STIMULUS N TOTAL OPIOID (NG/ML) 
PROP 
(UG/ML) 
Observed Loss  
of Responsiveness 
 
23 6.83±2.19 1.00±0.91 
13 NR 6.96±1.86 2.66±0.86 Laryngoscopy and 
Tracheal Intubation 11 R 5.81±1.45 2.31±0.64 
23 NR 5.90±1.94 2.82±0.66 First Skin Incision 1 R 4.23 1.57 
Observed Return of 
Responsiveness 23 2.83±1.59 1.95±0.42 
NR indicates the number of patients who did not respond to pain at the 
surgical milestone.  R indicates the number of patients who responded to 




For TI, four PK-PD combined models have a statistically 
significant relationship with the observations of the patients 
according to the two-tailed Fisher exact test relative to the 
95% isobol.  Due to a lack of PK-PD combined model 
predictions below 50%, the Fisher test could not be used for 
all PK-PD combinations.  However, for the few combinations 
that were tested relative to the 50% isobol, the predictions are 
apparently random.  According to the PK and the r
2 tests, the 
predictions are only slightly better than randomly guessing the 
anesthetic effect.  All the available p-values relative to the 
50% isobol, the lowest three p-values relative to the 95% 
isobol, the three highest PK-values, the three highest r
2-values, 
and the specific PK-PD combinations are in Table 5.   
For the SI data and using the two-tailed Fisher exact test 
relative to the 50% and 95% isobols, nine of 21 of the best p-
values were statistically significant.  Due to high PK-PD 
predictions, only five model combinations were tested relative 
to the 50% isobol.  However, these high predictions combined 
with only a single patient response to the first SI resulted in PK
 
and r2 average values of 0.989 and 0.9956 for the top 3 scores, 
respectively.  These results and the specific models are shown 
in Table 6.   
 
IV. DISCUSSION 
The aim of this study was to observe whether PK-PD model 
predictions were accurate predictors of anesthesia in the 
operating room at four clinical milestones.  We also hoped this 
study would help relate surrogate measures of pain to surgical 
stimuli.  However, the lack of measured drug concentrations, 
exasperated by a lack of control over individual dosing 
schemes, make it impossible to distinguish between 
pharmacokinetic and pharmacodynamic variances.  The 
pharmacodynamic relationship between the surgical stimuli 
and surrogate measures remains unclear.   
Though we observed patient responses to surgical 
stimulation throughout the entire surgery of each patient, we 
were unprepared for the subtle differences between 
cholecystectomies, hernia repairs, and nissen fundoplications.  
The four clinical milestones of LOR, ROR, TI, and SI were 
chosen because they were consistently identifiable for all these 
TIVA-appropriate surgeries.  Had we observed more patients 
for the same types of surgeries, we would expect to have 
reported on the PK-PD combined model predictions for other 
specific surgical stimuli.   
A fundamental challenge for this study was the degrees for 
freedom we allowed while considering numerous variables.   
For example, a key principle in creating and validating drug 
interaction models is to exercise control over the drug 
concentrations.  It was overly optimistic to forgo this control—
no plasma samples were taken and the anesthetists were only 
asked to follow their (individual) standard practices to provide 
total intravenous anesthesia using propofol and remifentanil as 
the primary anesthetic agents.   
We must also remember that although sedation was treated 
as a binary state in the operating room, it is actually a 
continuous measure.  This discrepancy is compounded by our 
inability to identifying the exact moments of LOR and ROR 
through some repeated stimulus requiring a single clear 
TABLE 6 
SUMMARY OF THE STATISTICAL TESTS FOR THE COMBINED PK-PD MODELS 
PREDICTING TI 
TEST 
AVERAGE OF TOP 















































TG, TS, G, and S refer to the Tackley-Gepts, Tackley-Schnider, Gepts, 
and Schnider propofol PK sets, respectively. 
1.2, 1.7, and 2.4 are the three fentanyl relative potencies modeled.   
Alg and Tet refer to the PD models of Kern et al. of shin algometry and 
electrical tetany, respectively.  
*’s refer to all applicable PK or PD models tested. 
TABLE 5 
SUMMARY OF THE STATISTICAL TESTS FOR THE COMBINED PK-PD MODELS 
PREDICTING SI 
TEST 
AVERAGE OF TOP 
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TG, TS, G, and S refer to the Tackley-Gepts, Tackley-Schnider, Gepts, 
and Schnider propofol PK sets, respectively. 
1.2, 1.7, and 2.4 are the three fentanyl relative potencies modeled.   
L, ML, and MI refer to the PD models of Kern et al. for Laryngoscopy,  
and of Mertens et al. for Laryngoscopy Alone, and of Mertens et al. Tracheal 
Intubation, respectively. 




response.  For example, in a controlled study environment, a 
volunteer may be queried 3 to 6 times a minute to observe the 
exact moment of LOR.  In our observational study, the 
moment of LOR was assessed by a research nurse watching the 
patient and the anesthesiologist but without addressing the 
patient.   
Because this study was only observational, tracheal 
intubation followed laryngoscopy as quickly as possible.  As a 
result, we were unable to separate these two milestones, 
making it difficult to observe the potential differences in 
predicting the anesthesia necessary for these two noxious 
stimuli. 
The milestone of SI also presented a surprising dilemma—
although we observed the first skin incision clearly, the 
second, third, fourth, etc. incisions were less obvious.  We 
wished to use all the data we had gathered from these 
observations, yet lack the statistical tools to know how to 
evaluate repeated stimuli in the same patient—this violates a 
fundamental assumption of independence, necessary for most 
statistical tests.   
Despite clear criteria to identify patient responses to pain, 
pain itself is a subjective measure.  Furthermore, the definition 
of “adequate anesthesia” is inexact.  For example, the 
anesthesiologist may respond to a 15% rise in heart rate by 
increasing the opioid.  Since we defined a heart rate response 
to pain to be a rise exceeding 20%, this episode was not 
considered a response to a noxious stimulus.  However, was 
“adequate anesthesia” provided seeing that the patient began to 
respond?  What would have been the ideal delivery of 
anesthesia, to prevent all responses to noxious stimuli, or to 
titrate the dosing in order to minimize the response itself?  In 
our study, we treated rising heart rates that were then 
controlled, as nonresponses to pain.  Our PD models were 
simply not designed to describe the continuous or graded 
nature of pain for an individual.  Instead, we assume this 
continuous scale to be somehow described by the population 
variance of a binary assessment of “adequate anesthesia.” 
Some may question the different methods of used to identify 
the most predictive PK-PD combined model.  We found a 
dearth of statistical methods designed specifically to validate 
response surface data in a monitoring environment.  We were 
disappointed that the Fisher exact test essentially reduces 
response surfaces into isobologram data.  It is also somewhat 
unwieldy, requiring the manual calculation of contingency 
tables relative to each isobol of interest.  Additionally, the PK-
test is not yet well understood, and appears to test the rank-
order of the data instead of directly evaluating the accuracy of 
the predictions themselves.  The r2-value fails to account for 
the spread of concentrations of the response surface data, but 
only compares the final PD prediction with the observations.  
It was our hope that this combination of statistical tests 
identified PK-PD combined models that have a positive 
predictive value.   
We recognize that this study does not provide a clear “gold 
standard” based on globally optimized data—we could have 
attempted to create a single overall PK-PD model by changing 
each single variable until we found a single optimal model.  
We were not so ambitious, realizing that with another data set, 
each PK and PD variable would change.  Such a study would 
also ignore the findings of previous research, and would thus 
prove inadaptable to new research.  This study hoped to take 
advantage of the best results from multiple studies to find a 
PK-PD combined model that works well.   
Future protocols would outline a slower induction by 
infusion, in order to minimize the differences between bolus 
and infusion pharmacokinetics and dynamics.  This slower 
induction would also increase the accuracy of the 
pharmacokinetic predictions by reducing the peak and drop-off 
of bolus kinetics that is particularly hard to predict.  Though 
plasma samples would help validate pharmacokinetic models, 
it is clear that the estimated Ceff would still need to be related 
to the observed pharmacodynamics.  An automated system that 
requires a response from the patient may provide a more 
consistent and precise measure of LOR and ROR.  Though 
hazarding statistical independence of measures, we would 
consider the use of repeated surgical stimuli, while titrating the 
dosing.  Titration throughout the surgery may result in a better 
evaluation of intraoperative PD models, such as for SI.  A 
similar scheme was successfully used by Mertens et al. to 
create a laryngoscopy response surface directly from patient 
data.   
Tracheal intubation is generally attempted when Ceffs are 
expected to be peaking.  Surprisingly, our data showed that 
laryngoscopy and tracheal intubation often occur after the 
concentrations had peaked and begun to stabilize.   
The large number of LOR PK-PD combined models 
providing accurate predictions compared to the fewer number 
of ROR PK-PD combined models is slightly surprising.  This 
difference may be due to PD hysteresis between LOR and 
ROR; it is recognized that both PK and PD change with the 
duration of surgery.  Due to a lack of assayed anesthetic 
concentrations, we are unable to confirm whether this was a 
significant factor in the relatively short surgeries that we 
observed.   
We believe another significant difference is the nature of the 
dosing at induction verses awakening—following a bolus 
(such as given at induction) the kinetics rise and fall rapidly 
while awakening at the end of surgery is at relatively steady-
state concentrations as the anesthetics are eliminated from the 
body.  Not only are bolus PK difficult to estimate, but PD 
responses are different depending on the dosing scheme.   
For TI and SI, the PK-PD combined model predictions were 
high enough that a contingency table relative to the 50% and 
95% isobols had columns filled with 0’s.  In other words, most 
of these predicted data points were on the “flat” portion of the 
response surface.  According to these model predictions, the 
patients would have been sufficiently anesthetized for TI and 
SI at lower dosing schemes.  Due to relatively high anesthetic 
concentrations at TI and SI, it is difficult to identify which PD 




response to these noxious stimuli.  This most clearly 
summarizes the challenge of an observational study—the 
conservative practice of clinicians’ results in very few 
responses to pain in patients, especially at early stages of the 
surgery.  A study titrating the anesthetic early on or by 
observing surgical stimuli later in the surgery might alleviate 
this challenge.  Merten et al. used a predefined protocol to 
titrate the drug in order to gather data both when anesthesia 
was adequate and inadequate.  However, repeated measures 
face the statistical challenge of losing their independence.  




The purpose of this experiment was to study the predictive 
value of combined PK-PD models.  The most frequent PK 
models for the best predictions of adequate anesthesia for all 
clinical stimuli are the Schnider propofol model and a fentanyl 
scaling factor of 1.2.  For the PD models, the OAA/S<2 model 
is the best for sedation (both LOR and ROR).  The 
laryngoscopy and the tracheal intubation models of Mertens et 
al. are equally predictive for TI and the electrical tetany model 
appears to be best for SI.  This observational study will 
hopefully serve as a preliminary step in applying PK and PD 
modeling clinically.   
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